


What is the Therapeutic Development Network (TDN?)

The TDN is an initiative of the Alpha-1 Foundation (A1F) to accelerate progress in drug development, improve care and lead to a cure for Alpha-1 Antitrypsin Deficiency (Alpha-1). This advanced clinical trial platform brings together Alphas, top specialists, researchers, clinical trial sites (healthcare centers that execute clinical trials) and biopharmaceutical partners to improve clinical trial design and recruitment, and to enhance patient-focused drug development programs.

At its core, the TDN serves a dual mission. First, it aims to quickly identify, and match Alphas interested in clinical trials with suitable opportunities. Second, it partners with the pharmaceutical industry and academic researchers to develop trials that reflect the experiences of the Alpha-1 community and execute these studies efficiently at centers with highly qualified staff. This precise, patient-centered approach streamlines recruitment while ensuring that clinical trials are conducted at the highest standards of care.

Scan the QR code to learn more.



The Alpha-1 Foundation (A1F) is committed to finding a cure for Alpha-1 Antitrypsin Deficiency (Alpha-1) and to improving the lives of people affected by Alpha-1 worldwide.

ALPHA1.ORG
1 (877) 2 CURE A1 | 1 (877) 228-7321

Unrestricted educational grants provided by:

AlphaNet
CSL
Grifols
Takeda



THERAPEUTIC DEVELOPMENT NETWORK (TDN)

Patient Centric Clinical Trials





What does joining the TDN mean?

By joining the TDN, you're taking an active role in shaping future clinical trials. With just a small amount of medical information, you will contribute to the thoughtful design of new clinical trials.

You may also be presented with opportunities to take part in research. When new clinical trials are available, those who may be a good fit will be contacted directly by an enrolling TDN center. Participation in any clinical trial is entirely optional and requires your consent, ensuring your involvement is always up to you.

How can Alphas join the TDN?

Alphas who wish to join the TDN can do so via their care center, if it is part of the Network, or through our virtual center. Participation begins with signing the TDN informed consent form, allowing the collection of targeted medical information and enabling future contact for matched clinical trials. Every 3-6 months, TDN participants are contacted for updates on their health and to ensure their medical records remain current.

Participation in the Alpha-1 Research Registry is also required, supporting A1F's mission to build a comprehensive database detailing the natural history of Alpha-1. Additionally, participants can permit their medical data collected by the TDN to be shared with the Alpha-1 Research Registry, further strengthening this vital resource.

To learn the differences between the Alpha-1 Research Registry and the TDN, please visit: alpha1.org/therapeutic-development-network/



For more information about the TDN and to join, contact:

 TDN@alpha1.org

Supporting Industry & Academia

The TDN team brings over a century of combined expertise in clinical trials and research operations, making it the most trusted resource in the field of Alpha-1. Importantly, the TDN team and the physicians and researchers within the network are readily available to assist industry and academic partners in optimizing clinical trial design and execution.

The TDN offers a comprehensive range of services tailored to support industry partners of all sizes and academic researchers who are focused on advancing treatments for Alpha-1. For more information about the TDN and to join, contact the TDN team today at TDN@alpha1.org or scan the QR code below to visit alpha1.org/therapeutic-development-network/

